Domperidone: Limited Benefits With Significant Risk for Sudden Cardiac Death
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Domperidone (antinausea/vomiting agent) was recently shown by several groups to increase sudden cardiac death (SCD). Drug-induced disturbances of cardiac repolarization may be a major mechanism. METHODS AND RESULTS: Experiments were executed in isolated female rabbit hearts perfused for 150 minutes with domperidone 30, 60, or 100 nM. Domperidone significantly prolonged the action potential duration: +9% at 30 nM, +32% at 60 nM, and +48% at 100 nM. Domperidone induced significant disturbances of repolarization in 83% of hearts at 60 nM and in 100% at 100 nM, including early afterdepolarizations and polymorphic ventricular tachycardia. Maximum therapeutic free drug plasma concentration of domperidone (19 nM) yields a safety index of only ∼2.5, that is, 12-fold below the accepted minimum. Gastrointestinal benefits and risks for SCD were derived from the literature. The defined daily dose of domperidone (30 mg/day) fails to show unequivocal gastrointestinal benefits beyond a placebo effect. In contrast, 5 of 5 population-based studies show that oral domperidone significantly increases the odds ratio for SCD to 2.8 (1.53-6.21) and it increases sharply above 30 mg/day. CONCLUSIONS: Because domperidone has placebo-like benefits but is associated with increased SCD and a narrow safety margin, it should not be used in medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to this, a severe warning has been reported for domperidone treatment due to the sudden risk of cardiac death observed at doses of more than 30 mg per day in the elderly [40–43].”
Citations
Cites
A Systematic Review of the Efficacy of Domperidone for the Treatment of Diabetic Gastroparesis
Sugumar, A., Singh, A., & Pasricha, P. J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.065 · Cited by 102 · cited 1×
“Of 6 recent review articles on diabetic gastroparesis, one systematically reviewed all available trials.(31) Of 9 recent reviews on prokinetic actions for use against nausea or vomiting, none provided a systematic evaluation nor included large enough trials to provide a clear conclusion.”
BackgroundImpaired Gastric Slow Waves Induced by Spatial Disorientation and Effect of Domperidone
Kono, T., Tokumaru, O., Mizumoto, C., Tatsuno, J., & Chen, J. D. Z. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01071.x · Cited by 9
Research works printed but not linked: 38
- Reddymasu, 2007, Am J Gastroenterol, 102, 2036, 10.1111/j.1572-0241.2007.01255.x · DOI · Paper page
- Straus, 2005, Eur Heart J, 26, 2007, 10.1093/eurheartj/ehi312 · DOI · Paper page
- De Bruin, 2006, Br J Clin Pharmacol, 63, 216, 10.1111/j.1365-2125.2006.02722.x · DOI · Paper page
- Hennessy, 2008, Pharmacoepidemiol Drug Saf, 17, 1131, 10.1002/pds.1632 · DOI
- van Noord, 2010, Drug Saf, 33, 1003, 10.2165/11536840-000000000-00000 · DOI
- Johannes, 2010, Pharmacoepidemiol Drug Saf, 19, 881, 10.1002/pds.2016 · DOI · Paper page
- Giaccone, 1984, Lancet, 2, 1336, 10.1016/S0140-6736(84)90841-9 · DOI
- Joss, 1982, Lancet, 1, 1019, 10.1016/S0140-6736(82)92016-5 · doi:10.1016/s0140-6736(82)92016-5
- Roussak, 1984, Br Med J, 289, 1579, 10.1136/bmj.289.6458.1579 · DOI · Paper page
- Osborne, 1985, Lancet, 2, 385, 10.1016/S0140-6736(85)92515-2 · DOI
- Bruera, 1986, Cancer Treat Rep, 70, 545
- Osborne, 1985, Hum Toxicol, 4, 617, 10.1177/096032718500400608 · doi:10.1177/096032718500400608
- Rossi, 2010, Curr Drug Saf, 5, 257, 10.2174/157488610791698334 · DOI · Paper page
- Drolet, 2000, Circulation, 102, 1883, 10.1161/01.CIR.102.16.1883 · DOI · Paper page
- Hondeghem, 2011, Acta Cardiol, 6, 421, 10.1080/AC.66.4.2126588 · DOI
- Hondeghem, 2003, J Cardiovasc Electrophysiol, 14, 287, 10.1046/j.1540-8167.2003.02466.x · DOI
- Hondeghem, 2001, Circulation, 103, 2004, 10.1161/01.CIR.103.15.2004 · DOI · Paper page
- Claassen, 2005, Pharmacology, 74, 31, 10.1159/000083234 · DOI · Paper page
- Redfern, 2003, Cardiovasc Res, 58, 32, 10.1016/S0008-6363(02)00846-5 · DOI · Paper page
- Hondeghem, 2008, Eur J Pharmacol, 584, 1, 10.1016/j.ejphar.2008.01.016 · DOI
- Hondeghem, 1994, J Cardiovasc Electrophysiol, 5, 711, 10.1111/j.1540-8167.1994.tb01193.x · doi:10.1111/j.1540-8167.1994.tb01193.x
- Itoh, 2005, Biol Pharm Bull, 28, 1752, 10.1248/bpb.28.1752 · DOI
- Hondeghem, 2011, J Cardiovasc Pharmacol, 57, 589, 10.1097/FJC.0b013e3182135e91 · DOI
- Pritchard, 2005, Br J Clin Pharmacol, 59, 725, 10.1111/j.1365-2125.2005.02422.x · doi:10.1111/j.1365-2125.2005.02422.x
- Tighe, 2009, Paediatr Drugs, 11, 185, 10.2165/00148581-200911030-00004 · doi:10.2165/00148581-200911030-00004
- Lewis, 1926, Heart, 13, 95
- Shah, 2005, Heart Rhythm, 2, 758, 10.1016/j.hrthm.2005.03.023 · DOI · Paper page
- Maddern, 1986, J Clin Gastroenterol, 8, 135, 10.1097/00004836-198604000-00006 · DOI
- Sakamoto, 2011, Hepatogastroenterology, 58, 637
- Markey, 2012, Ir J Med Sci, 181, 215, 10.1007/s11845-011-0785-2 · DOI
- Prakash, 1998, Drugs, 56, 429, 10.2165/00003495-199856030-00011 · DOI
- Takahashi, 1991, Gastroenterology, 101, 703, 10.1016/0016-5085(91)90528-S · DOI
- Braun, 1989, Adv Ther, 6, 51
- Lu, 2001, J Cardiovasc Electrophysiol, 12, 93, 10.1046/j.1540-8167.2001.00093.x · DOI · Paper page
- Ward, 2004, Br J Pharmacol, 58, 277, 10.1111/j.1365-2125.2004.02156.x · DOI · Paper page
- Couture, 2006, Pharmacol Rev, 58, 244, 10.1124/pr.58.2.7 · DOI
- Reiche, 2011, J Pharm Sci, 100, 2469, 10.1002/jps.22437 · DOI
- De Ponti, 2002, Br J Clin Pharmacol, 54, 171, 10.1046/j.1365-2125.2002.01617.x · DOI · Paper page
Cited by
Giacosa, A., Guido, D., Grassi, M., Riva, A., Morazzoni, P., Bombardelli, E., Perna, S., Faliva, M. A., & Rondanelli, M. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/915087 · Cited by 72
“In addition to this, a severe warning has been reported for domperidone treatment due to the sudden risk of cardiac death observed at doses of more than 30mg per day in the elderly [40–43].”
BackgroundMishra, H., Polak, S., Jamei, M., & Rostami‐Hodjegan, A. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.26 · Cited by 24
Metadata
- Authors
- Hondeghem, L. M.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2013-03
- Volume
- 61
- Issue
- 3
- Pages
- 218-225
- ISSN
- 0160-2446
- Cited by
- 53
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Domperidone: Limited Benefits With Significant Risk for Sudden Cardiac Death. https://app.cochat.ai/papers/10.1097/fjc.0b013e31827afd0d
- The paper
- Hondeghem, L. M. (2013). Domperidone: Limited Benefits With Significant Risk for Sudden Cardiac Death. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0b013e31827afd0d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.